Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients

Regulatory Peptides

Volumn 168, Issue 1-3, 2011, Pages 39-44

  Villanueva Peñacarrillo, María L ^a   Martín Duce, Antonio ^b   Ramos Álvarez, Irene ^a   Gutiérrez Rojas, Irene ^a   Moreno, Paola ^a   Nuche Berenguer, Bernardo ^a   Acitores, Alicia ^a   Sancho, Verónica ^a   Valverde, Isabel ^a   González, Nieves ^a  

^a Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

GLP 1; Glucose metabolism; Human muscle; Obesity

Indexed keywords

AMIDE; CELL PROTEIN; EXENDIN[1-39]AMIDE; EXENDIN[9-39]AMIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE ALPHA; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P70SK6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MORBID OBESITY; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; AGED, 80 AND OVER; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; MALE; MUSCLE, SKELETAL; OBESITY, MORBID; PEPTIDE FRAGMENTS;

RATTUS;

EID: 79955675087     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.03.002     Document Type: Article

References (43)

1. Creutzfeldt W. The entero-insular axis in type-2 diabetes. Incretins as therapeutic agents. Exp Clin Endocrinol Diab 2001, 109(Suppl. 2):S288-S303.
2. Gutniak M., Orskov C., Holst J.J., Ahrén B., Efendic S. Antidiabetogenic effects of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992, 326:1316-1322.
3. D'Alessio D.A., Prigeon R.L., Ensinck J.W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 1995, 44:1433-1437.
4. Valverde I., Morales M., Clemente F., López-Delgado M.I., Delgado E., Perea A., Villanueva-Peñacarrillo M.L. Glucagon-like peptide-1: a potent glycogenic hormone. FEBS Lett 1994, 349:313-316.
5. Villanueva-Peñacarrillo M.L., Alcántara A., Clemente F., Delgado E., Valverde I. Potent glycogenic effect of GLP-1 (7-36)amide in rat skeletal muscle. Diabetologia 1994, 37:1163-1166.
6. Morales M., López-Delgado M.I., Alcántara A., Luque M.A., Clemente F., Márquez L., Puente J., Viñambres C., Malaisse W.J., Villanueva-Peñacarrillo M.L., Valverde I. Preserved GLP-1 effects upon glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997, 46:1264-1269.
7. Luque M.A., González N., Márquez L., Acitores A., Redondo A., Morales M., Valverde I., Villanueva-Peñacarrillo M.L. GLP-1 and glucose metabolism in human myocytes. J Endocrinol 2002, 173:465-473.
8. Acitores A., González N., Sancho V., Arnés L., Valverde I., Malaisse W., Villanueva-Peñacarrillo M.L. Participation of protein kinases in the stimulant action of GLP-1 upon 2-deoxy-d-glucose uptake by normal rat skeletal muscle. Horm Metab Res 2005, 37:275-280.
9. González N., Acitores A., Sancho V., Valverde I., Villanueva-Peñacarrillo M.L. Effect of GLP-1 on glucose transport and its cell signaling in human myocytes. Regul Pept 2005, 126:203-211.
10. González N., Sancho V., Martín-Duce A., Tornero-Esteban P., Valverde I., Malaisse W.J., Villanueva-Peñacarrillo M.L. GLP-1 signalling and effects on glucose metabolism in myocytes from type-2 diabetic patients. Int J Mol Med 2005, 16(4):747-752.
11. Sancho A., Trigo M.V., González N., Valverde I., Malaisse W.J., Villanueva-Peñacarrillo M.L. Effects of glucocagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol 2005, 35:27-38.
12. Sancho V., Trigo M.V., Martín-Duce A., González N., Acitores A., Arnés L., Valverde I., Malaisse W.J., Villanueva-Peñcarrillo M.L. Effect of GLP-1 on d-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 2006, 17:1133-1137.
13. Redondo A., Trigo M.V., Acitores A., Valverde I., Villanueva-Peñacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003, 204:43-50.
14. Nuche-Berenguer B., Moreno P., Esbrit P., Dapía S., Caeiro J.R., Cancelas J., Haro-Mora J.J., Villanueva-Peñacarrillo M.L. Effect of GLP-1 treatment on bone turnover in normal, type-2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009, 84(6):453-461a.
15. Mérida E., Delgado E., Molina L.M., Villanueva-Peñacarrillo M.L., Valverde I. Presence of glucagon and glucagon-like peptide-1(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993, 77:1654-1657.
16. Delgado E., Luque M.A., Alcántara A., Trapote M.A., Clemente F., Galera C., Valverde I., Villanueva-Peñacarrillo M.L. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 1995, 16:225-229.
17. Villanueva-Peñacarrillo M.L., Delgado E., Trapote M.A., Alcántara A.I., Clemente F., Luque M.A., Perea A., Valverde I. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995, 146:183-189.
18. Villanueva-Peñacarrillo M.L., Delgado E., Vicent D., Mérida E., Alcántara A.I., Valverde I. GLP-1(7-36)amide binding in skeletal muscle membranes from streptozotocin diabetic rats. Endocr 1995, 3:685-687.
19. Valverde I., Mérida E., Delgado E., Trapote M.A., Villanueva-Peñacarrillo M.L. Presence and characterization of glucagon-like peptide-1(7-36)amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 1993, 132:75-79.
20. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci U S A 1992, 89:8641-8645.
21. Márquez L., Trapote M.A., Luque M.A., Valverde I., Villanueva-Peñacarrillo M.L. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue. Cell Biochem Funct 1998, 16:51-56.
22. Marquéz L., González N., Luque M.A., Villanueva-Peñacarrillo M.L., Valverde I. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats. Diab Nutr Metab 2001, 14:239-244.
23. Nuche-Berenguer B., Portal-Núñez S., Moreno P., González N., Acitores A., López-Herradón A., Esbrit P., Valverde I., Villanueva-Peñacarrillo M.L. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010, 225(2):585-592.
24. Mentlein R. Mechanism underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009, 23(4):443-452.
25. Alcántara A.I., Morales M., Delgado E., López-Delgado M.I., Clemente F., Luque M.A., Malaisse W.J., Valverde I., Villanueva-Peñacarrillo M.L. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997, 341:1-7.
26. Nuche-Berenguer B., Moreno P., Portal-Nuñez S., Dapía D., Esbrit P., Villanueva-Peñacarrillo M.L. Exendin-4 exerts osteogenic actions in insulin-resistant and type-2 diabetic states. Reg Pept 2009, 159:61-66.
27. Nielsen L.L., Young A.A., Parkers D.G. Pharmacology of exenatide (synthetic exedin-4): a potential therapeutic for improved glycemic control of type-2 diabetes. Reg Pept 2004, 117:77-88.
28. Montrose-Rafizadeh C., Yang H., Wang Y., Roth J., Montrose M.H., Adams L.G. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 1997, 172:275-283.
29. Yang H., Egan J.M., Wang Y., Moyes D., Roth J., Montrose M.H., Montrose-Rafizadeh C. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 1998, 275:C675-C683.
30. Villanueva-Peñacarrillo M.L., Márquez L., González N., Díaz Miguel M., Valverde I. Effect of GLP-1 on lipid, metabolism in human adipocytes. Horm Metab Res 2001, 33:73-77.
31. Sancho V., Nuche B., Arnés L., Cancelas J., González N., Díaz-Miguel M., Martín-Duce A., Valverde I., Villanueva-Peñacarrillo M.L. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int J Mol Med 2007, 19:961-966.
32. Ranganath L.R., Beety J.M., Morgan L.M., Wright A.L., Howland R., Marks V. Attenuated GLP-1 secretation in Obesity: cause or consequence?. Gut 1996, 38:916-919.
33. Valverde I., Puente J., Martín-Duce A., Molina L., Lozano O., Sancho V., Malaisse W.J., Villanueva-Peñacarrillo M.L. Changes in glucagon-like peptide-1 (GLP-1) secretation after biliopancreatic diversión or vertical banded gastroplasty in obese subjects. Obs Surg 2005, 15:387-397.
34. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976, 72:248-254.
35. Cancelas J., Villanueva-Peñacarrillo M.L., Valverde I., Malaisse W.J. Potentiaton by glutamic acid dimethyl ester of GLP-1 insulinotropic action in fed anaesthetized rats. Int J Mol Med 2001, 8(5):531-532.
36. Sheperd P.R., Kahn B.B. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 1999, 341:248-257.
37. Pedersen O., Bak J.F., Andersen P.H., Lund S., Moller D.E., Flier J.S., Kahn B.B. Diabetes 1990, 39(7):865-870.
38. Björnholm M., Kawano Y., Lehtihet M., Zierath J.R. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 1997, 46(3):524-527.
39. Miura T., Suzuki W., Ishihara E., Arai I., Ishida H., Seino Y., Tanigawa K. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type-2 diabetes. Eur J Endocrinol 2001, 145(6):785-790.
40. Golay A., Munger R., Franccediloise Assimacopoulos Jeannet Elisabetta Bobbioni-Harsch FAJE, Habicht F., Felber J.P. Progressive defect of insulin action on glycogen synthase in obesity and diabetes. Metabolism 2002, 51(5):549-553.
41. Henriksen E.J. Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type-2 diabetes. Curr Diab Rev 2010, 6(5):285-293.
42. Arnés L., González N., Tornero-Esteban P., Sancho V., Acitores A., Valverde I., Delgado E., Villanueva-Peñacarrillo M.L. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med 2008, 22(1):127-132.
43. Meyer M.M., Levin K., Grimmsmann T., Beck-Nielsen H., Klein H.H. Insulin signaling in skeletal muscle of subjects with or without type II-diabetes and first degree relatives of patients with disease. Diabetologia 2002, 45:813-822.